The "tumor detection leader" Ruiang Gene boss sister and brother were "one pot end"!

Bronco Finance

2024-07-28 18:36Posted on the official account of Shanxi Bronco Finance

The full text is 2795 words, and it takes about 8 minutes to read, so help me highlight the key points

Highlight the point

01 Four senior executives, including the actual controller, general manager and deputy general manager of Ruiang Gene, a listed company in the field of tumor testing, were taken compulsory measures, and the stock price once fell to the limit.

02 Among them, Deputy General Manager He Junyan was criminally detained on suspicion of illegal operation, and other executives such as Xiong Hui, Xiong Jun and Xue Yuwei were placed under residential surveillance at a designated location on suspicion of illegal operation.

03Due to major changes in the senior management team, the stock price of Ruiang Gene fell by 31% from July 23 to 24, and then began to pull back.

04 The company said that it is currently unable to assess whether the performance target and product target in 2023 can be completed as planned, and investors are requested to pay attention to the follow-up announcement.

05In addition, Ruiang Gene had planned to build an agent system in 2024 to promote the "admission of licensed exclusive products" to increase sales.

The above content is generated by Tencent's hybrid model and is for reference only

The four major executives were "ended", can the sales target still be achieved?

Author | Zhao Pu

Editor丨Gao Yuanshan

Source | Bronco Finance

Another A-share listed company has attracted market attention because of the "one-pot end" of its executives! In one day, the company's actual controller, general manager, deputy general manager and other four senior executives were taken compulsory measures, and the stock price also fell for a time.

This company is the company that focuses on the field of tumor detection, Ruiang Gene (688217. SH), the company recently announced that the company's actual controller, chairman and general manager, core technical personnel Xiong Hui, actual controller, director and deputy general manager Xiong Jun, deputy general manager Xue Yuwei, were taken by the public security organs for suspected illegal business surveillance at a designated location; Deputy General Manager He Junyan was taken into criminal detention by the public security authorities on suspicion of illegal operation, and related matters are pending further investigation.

Source: Company announcement

It is understood that the founder of Ruiang Gene is Xiong Hui, and Xiong Jun is a sister and brother, both of whom are the actual controllers of Ruiang Gene.

The secretary of the board of directors of Ruiang Gene replied to the investors that the projects and products that Xiong Hui was mainly responsible for were still advancing as planned, and the company has elected Gao Shangxian to perform the duties of the company's legal representative, chairman and general manager, as well as the duties of relevant committee members of the company's board of directors.

After this sharp drop in stock price, as of the close of trading on July 26, the share price of Ruiang Gene was 13.17 yuan per share, with a total market value of only 736 million yuan.

Ruiang Gene once said that it would "create another Ruiang" and "bring hope for the continuation of life to Chinese cancer patients", but now it has suffered a major personnel change in the middle of expansion, and it seems that "Ruiang" needs to give itself "hope for continuity" to realize the company's vision.

The vice president was criminally detained, and he was mainly involved in pharmaceutical sales

The above four senior executives were "one pot end", which means that 1 general manager and 3 deputy general managers of Ruiang Gene are unable to manage the company's business normally, and only Ms. Zhang Chengli and Ms. Xie Liqun are left with only two deputy general managers, of which Xie Liqun is also the core technical personnel.

Bronco Finance noticed that among the above four executives, Deputy General Manager He Junyan was suspected of illegal business and was taken into criminal detention by the public security organs, which was more serious.

Although Ruiang Gene did not disclose the specific content of the above four executives' alleged violations, the resume shows that He Junyan, who is the most serious in nature, has many years of work experience in the field of pharmaceutical sales, and has a close working relationship with Xiong Jun, the younger brother of the actual controller Xiong Hui.

Source: Canned Gallery

Born in 1973, He Junyan served as a resident physician in the Department of Oncology of Huangpu District Central Hospital for two years, and then worked in the pharmaceutical sales management and marketing department of a number of multinational companies for about ten years, and was responsible for the management of national sales, marketing, business, and key accounts of domestic pharmaceutical companies Yiteng Pharmaceutical Group Co., Ltd. and Fujian Guangshengtang Pharmaceutical Co., Ltd. from 2016 to 2019.

In June 2019, He Junyan joined Xiong Hui's company, and was successively responsible for the preparation, daily management and promotion and sales of laboratory projects in Wuhan Sitide, Beijing Sitech and Shanghai Sitide, and has been the supervisor of Ruiang Gene Beijing Laboratory since November 2022, and the deputy general manager of Ruiang Gene since April 2023.

It is worth noting that Wuhan Si Taide, Beijing Si Tai De and Shanghai Si Tai De are all wholly-owned subsidiaries of Shanghai Si Taide Biotechnology Co., Ltd. (hereinafter referred to as "Si Taide Biotechnology"), and the actual controller is Xiong Hui.

Source: Enterprise Early Warning

In addition, since June 2020, He Junyan has also served as the executive partner of Shanghai Xinyi Business Consulting Center (Limited Partnership), which is the only foreign investment company and is also the company of Si Taide Biotech.

According to public data, the net profit of Si Taide Bio in 2022 ~ 2023 will continue to lose, with losses of 658,600 yuan and 517,500 yuan respectively, and the net profit of its subsidiaries Wuhan Si Tai De, Beijing Si Tai De and Shanghai Si Tai in 2023 will also be losses.

Source: The company's 2023 financial report

It is also understood that Xiong Hui's younger brother Xiong Jun has served as the executive director and general manager of Sitide Biotechnology since June 2020, the executive director of Beijing Sitech since June 2020, and the executive director of Wuhan Sitech since July 2020.

It can be seen that since June 2020, Xiong Jun and He Junyan have both worked in the two subsidiaries of Beijing Sitech and Wuhan Sitaide, and their working relationship is closer.

Before Xiong Jun joined his sister's company, he was an architectural decoration designer and did not focus on the pharmaceutical industry. According to the data, from July 1999 to November 2012, Xiong Jun worked as a designer and project manager in Shanghai Architectural Decoration Engineering Co., Ltd., Shanghai Guanghua Survey and Design Institute Co., Ltd., and Shanghai Jingwei Architectural Planning and Design Institute Co., Ltd.

Since November 2012, Xiong Jun has successively served as an executive director or general manager of Yuanqi Biotechnology, Si Tai Biotechnology, Beijing Si Tai De and Wuhan Si Tai under his sister Xiong Hui, and has been a director and deputy general manager of Ruiang Gene since January 2015.

According to the financial report, after changing careers from architectural design to the pharmaceutical industry, Xiong Jun's annual salary in Ruiang Gene in 2023 will be 530,400 yuan.

Promote two vice presidents for "increasing revenue",

Can Xiong Hui's "medical dream" be realized?

After the news that four executives including two actual controllers were taken compulsory measures, the share price of Ruiang Gene fell by 31% in two days on July 23~24, and began to pull back on July 25.

It is understood that Ruiang Gene was established in December 2018, which was changed from Shanghai Ruiang Biotechnology Co., Ltd., and the founder was Xiong Hui.

Listed on the Shanghai Stock Exchange on May 17, 2021, Ruiang Gene's main products are molecular diagnostic reagent products and related scientific research and testing services, focusing on the research and development of tumor molecular diagnostic reagents.

Financial data show that the performance of Ruiang Gene has changed rapidly before and after listing, with its revenue in 2020~2022 being about 285 million yuan, 291 million yuan and 424 million yuan respectively, and net profit of about 38.71 million yuan, 47.33 million yuan and 40.47 million yuan respectively, but the net profit in 2023 will take a sharp turn to 7.931 million yuan and revenue of 258 million yuan.

Source: Oriental Fortune Network

Ruiang Gene said that the year-on-year decline in operating income in 2023 was mainly due to the decline in testing business revenue, and the increase in fixed costs such as accumulated depreciation and personnel made the period expenses slightly higher than that of the previous year, resulting in a decline in net profit.

In addition, in 2023, the senior management of Ruiang Gene will change frequently, with a total of 1 director, 1 independent director, and 2 supervisors leaving, and 3 senior managers hired in the same year, including He Junyan and Xue Yuwei. Xue Yuwei was not in Ruiang Gene before, but worked as a product manager or marketing manager in Roche Diagnostics Co., Ltd., Abbott Co., Ltd., AstraZeneca China (Investment) Co., Ltd., Beijing Peng'an Health Consulting Co., Ltd. and other companies.

Why were He Junyan and Xue Yuwei promoted to deputy general managers? This is related to the strategic layout of Ruiang Gene.

One is to build an agent system in 2024 to accelerate hospital admission with the help of agents, and promote the company's products to grassroots hospitals; Second, Ruiang Gene also plans to hire a consulting company to carry out corresponding training for the management team, reform the sales system, refine the responsibilities of sales personnel, and improve the professional ability of sales personnel.

In addition, the remaining two "battles" of Ruiang Gene are actually related to sales, which are to promote the admission of "certified exclusive products" to increase sales, and to promote the standardized admission of NGS products and services.

According to reports, Ruiang Gene currently has a total of lymphoma gene rearrangement detection kits, leukemia 15 fusion gene detection kits and the exclusive agent of Otsuka Pharmaceutical's WT1 assay kit and other products have been approved, all of which are exclusive products in China.

Talking about whether the annual performance target and product target of Ruiang Gene can be completed as planned, the secretary of the board of directors said that it is impossible to evaluate it at present, and investors should pay attention to the follow-up announcement.

"(The company) has brand and technical advantages in the field of hematology and lymphoma, and is actively participating in relevant pilot and bidding work." Ruiang Gene said.

It is understood that as an IVD (in vitro diagnostic) company, Ruiang Gene is a life science enterprise with its own brand of testing instruments, testing reagents and third-party laboratories.

Ruiang Gene has a new five-year plan to "rebuild another Ruiang", and 2024 is the fourth year of this plan.

According to the Beijing News, the founder, Xiong Hui, 51, graduated from Fudan University with a major in microbiology and worked as an assistant researcher at the Shanghai Institute of Hematology at Ruijin Hospital affiliated to Shanghai Second Medical University before going to United States for postdoctoral studies in 2002. After returning to China in 2005, he served as the general manager of Shanghai Shenyou Biotechnology Co., Ltd., and from January 2010 to the present, he has successively founded Yuanqi Biotechnology and Ruiang Co., Ltd., responsible for the overall operation of the company.

Xiong Hui has also successfully developed the first HBV drug resistance mutation detection kit based on the first-generation sequencing platform for clinical application in China. By the end of 2023, Xiong Hui holds about 10,176,400 shares of Ruiang Gene, with a shareholding ratio of 18.22%.

According to the China Securities Journal, Xiong Hui is one of the few female "heads" on the stage of the Science and Technology Innovation Board, and has successively studied under academician-level biology masters such as Chen Zhu, Chen Saijuan, and Zhao Guoping.

The above-mentioned media also quoted Xiong Hui as saying, "We hope to truly empower the service capabilities of Ruiang Gene in tumor testing to the primary medical market and benefit more people." ”

Now, Xiong Hui and his younger brother Xiong Jun and the two vice presidents of the company have been taken compulsory measures together, and only by finding out the illegal acts as soon as possible and rectifying them can they continue to realize Xiong Hui's "medical dream".

Can Ruiang Gene smoothly survive the "shock period" of senior management? Let's talk in the comment section.

View original image 647K

• 

• 

• 

• 

• 

• 

•